Your browser doesn't support javascript.
loading
The benefits of adipocyte metabolism in bone health and regeneration.
Burkhardt, Lisa-Marie; Bucher, Christian H; Löffler, Julia; Rinne, Charlotte; Duda, Georg N; Geissler, Sven; Schulz, Tim J; Schmidt-Bleek, Katharina.
Afiliación
  • Burkhardt LM; Julius Wolff Institute, Berlin Institute of Health (BIH) Charité, Berlin, Germany.
  • Bucher CH; BIH Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin, Berlin, Germany.
  • Löffler J; Julius Wolff Institute, Berlin Institute of Health (BIH) Charité, Berlin, Germany.
  • Rinne C; BIH Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin, Berlin, Germany.
  • Duda GN; Julius Wolff Institute, Berlin Institute of Health (BIH) Charité, Berlin, Germany.
  • Geissler S; BIH Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin, Berlin, Germany.
  • Schulz TJ; Department of Adipocyte Development and Nutrition, German Institute of Human Nutrition, Potsdam-Rehbrücke, Nuthetal, Germany.
  • Schmidt-Bleek K; Julius Wolff Institute, Berlin Institute of Health (BIH) Charité, Berlin, Germany.
Front Cell Dev Biol ; 11: 1104709, 2023.
Article en En | MEDLINE | ID: mdl-36895792
ABSTRACT
Patients suffering from musculoskeletal diseases must cope with a diminished quality of life and an increased burden on medical expenses. The interaction of immune cells and mesenchymal stromal cells during bone regeneration is one of the key requirements for the restoration of skeletal integrity. While stromal cells of the osteo-chondral lineage support bone regeneration, an excessive accumulation of cells of the adipogenic lineage is thought to promote low-grade inflammation and impair bone regeneration. Increasing evidence indicates that pro-inflammatory signaling from adipocytes is responsible for various chronic musculoskeletal diseases. This review aims to summarize the features of bone marrow adipocytes by phenotype, function, secretory features, metabolic properties and their impact on bone formation. In detail, the master regulator of adipogenesis and prominent diabetes drug target, peroxisome proliferator-activated receptor γ (PPARG), will be debated as a potential therapeutic approach to enhance bone regeneration. We will explore the possibilities of using clinically established PPARG agonists, the thiazolidinediones (TZDs), as a treatment strategy to guide the induction of a pro-regenerative, metabolically active bone marrow adipose tissue. The impact of this PPARG induced bone marrow adipose tissue type on providing the necessary metabolites to sustain osteogenic-as well as beneficial immune cells during bone fracture healing will be highlighted.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Cell Dev Biol Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Cell Dev Biol Año: 2023 Tipo del documento: Article País de afiliación: Alemania